ClinicalTrials.gg
CompletedNCT00774761Updated May 20, 2013

A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease

A Phase 2 interventional study of fluticasone propionate/formoterol fumarate and fluticasone propionate in Chronic Obstructive Pulmonary Disease, sponsored by Dey. Completed at 12 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2013-05-20.

Sponsored by Dey (part of Viatris Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
97
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 4 under way, 1 of them phase 3. Fluticasone · Pulmonary Disease, Chronic Obstructive.

Enrollment
29th of 59
97 · median 95
Started
2008
with 1 other
Phase 2
10 of 59
none open now
Registered
12th of 59
by date
Lead sponsor
3 of 59
Dey

Among the 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive, this one is the 29th largest by enrollment, is one of 2 that started in 2008, is one of 10 in phase 2, and was the 12th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the systemic exposure and pharmacodynamics of two doses of nebulized fluticasone/formoterol combination as compared to the monocomponents.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Chronic
  • Obstructive
  • Pulmonary
  • Disease
  • COPD
  • Pharmacodynamic
  • Pharmacokinetic
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to understand the requirements of the study and provide consent
  • Medical diagnosis of
  • A current or prior history of at least 10-pack years of cigarette smoking
  • Female of to use adequate

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of asthma
  • Other significant disease than
  • Has donated a unit of blood within 30 days of study, or intends to donate
  • greater than 0.460 seconds
  • Subjects who had radiation or chemotherapy in the previous 12 months
  • Subjects who had lung resection
  • History of illegal drug abuse or alcohol abuse within the past 5 years
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    1

    Drug: fluticasone propionate/formoterol fumarate

  • Experimental
    2

    Drug: fluticasone propionate/formoterol fumarate

  • Active comparator
    3

    Drug: fluticasone propionate

  • Active comparator
    4

    Drug: fluticasone propionate

  • Active comparator
    5

    Drug: formoterol fumarate

Interventions

06

What researchers measure

Primary outcomes

  1. Plasma AUC(0-t) after 1 week of dosing

    Time frame: PK sampling over 24 hrs

Secondary outcomes

  1. FEV1

    Time frame: pre-dose and 2 hrs post-dose

07

Study locations

12 sites
  • Investigative Site
    San Diego, California 92120, United States
  • Investigative Site
    Panama City, Florida 32405, United States
  • Investigative Site
    Madisonville, Kentucky 42431, United States
  • Investigative Site
    Sunset, Louisiana 70584, United States
  • Investigative Site
    Charlotte, North Carolina 28207, United States
  • Investigative Site
    Medford, Oregon 97504, United States
  • Investigative Site
    Greenville, South Carolina 29615, United States
  • Investigative Site
    Spartanburg, South Carolina 29303, United States
  • Investigative Site
    Union, South Carolina 29379, United States
  • Investigative Site
    San Antonio, Texas 78205, United States
  • Investigative Site
    Spokane, Washington 99207, United States
  • Investigative Site
    Tacoma, Washington 98405, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Apr 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2008
First posted
Oct 17, 2008
Start
Nov 2008
Primary completionActual
Apr 2009
CompletionActual
May 2009
Results delay requested
May 10, 2013
Last update
May 20, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00774761
Lead sponsor
Dey
Responsible party
Sponsor
First posted
Oct 17, 2008
Start date
Nov 2008
Primary completion
Apr 2009
Completion
May 2009
Last update
May 20, 2013

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone · Formoterol

Start the discussion